SEC Filing Timeline
8-KNov 12, 2026
Earnings release · Items 2.02,9.01
10-QNov 05, 2026
Quarterly report
8-KNov 05, 2026
Earnings release · Items 2.02,9.01
8-KSep 08, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KSep 04, 2026
Material agreement · Items 1.01,2.03,7.01,9.01
10-QAug 06, 2026
Quarterly report
8-KAug 06, 2026
Earnings release · Items 2.02,9.01
8-KJun 15, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJun 10, 2026
Shareholder vote results · Items 5.07
Recent News (Finnhub)
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at AC…
Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
3 Gene Editing Stocks Retail Investors Are Watching After BioAdvance
Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)